{
  "docId": "019de073-bcea-715e-8f3b-2af68c1e6615",
  "docSlug": "cfcb19cc2b89b85461a28b4631a8b033",
  "documentTitle": "Hepion Pharmaceuticals | Results Presentation Deck | 34 slides",
  "authorId": "hepion-pharmaceuticals",
  "authorName": "Hepion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 23,
  "pageCount": 34,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "other",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide outlines a randomized clinical trial structure with a 1:1:1:1 ratio, a 12-month treatment period, and a 1-month follow-up.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-bcea-715e-8f3b-2af68c1e6615/23",
  "deckHref": "/decks/019de073-bcea-715e-8f3b-2af68c1e6615",
  "deckJsonHref": "/decks/019de073-bcea-715e-8f3b-2af68c1e6615.json",
  "deckAnchorHref": "/decks/019de073-bcea-715e-8f3b-2af68c1e6615#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.72,
        "y": 0.38
      },
      "kind": "callout",
      "text": "AI-POWR identification of biomarkers of Rencofilstat response. Data to inform phase 3 trial patient selection and biomarkers for analysis.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c560133e-b37e-483f-a583-071d5426d0b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.65,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "diagram",
      "text": "Trial timeline showing randomization at month 1, treatment until month 12, and off-treatment until month 13.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16e93ff5-b489-4111-a87f-fc0db2bc10aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.06,
        "y": 0.85
      },
      "kind": "list",
      "text": "Power = 90% to distinguish outcomes at each dosing level; FDA feedback obtained – study design endorsed; Blinded interim analyses when 1/3 of subjects in each cohort reach day 180 and when 2/3 of subjects in each cohort reach day 365",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "543b86d7-19fa-4566-aedb-ce89652b5e8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.06,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Primary Objective: Evaluate the efficacy and safety of once-daily 75mg, 150 mg, and 225 mg doses of Rencofilstat compared to placebo in subjects with biopsy proven NASH and stage 2 liver fibrosis (F2) / stage 3 liver fibrosis (F3)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a500fd3c-52d7-4c68-9e36-c27d8cdae3cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 2b ASCEND-NASH (Biopsy Trial)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "433b9e83-c35b-44bf-8811-b7338b6d168e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "b824783e-23f0-4759-bec6-79cfbba16a6e",
      "evidence": "paragraph/paragraph: Primary Objective: Evaluate the efficacy and safety of once-daily 75mg, 150 mg, and 225 mg doses of Rencofilstat compared to placebo in subjects with biopsy proven NASH and stage 2 liver fibrosis (F2",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "0afb6df1-eb95-4af3-bad8-bc46a8b25195",
      "evidence": "The timeline visualization of trial phases and cohorts.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}